Tricyclic 5,6-dihydro-9h-pyrazolo3,4-c-1,2,4-triazolo4,3-.alpha.pyridines
CA 2223624 C · Owner: Cooper, Kelvin · Inventors: Duplantier, Allen J.; Cooper, Kelvin
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A compound of formula (I), wherein R1, R2 R3, R9 and R10 are as defined in , the description. The compound of formula (I) and the pharmaceutically acceptable salts thereof are useful in inhibiting phosphodiesterase (PDE) Type IV and the production of tumor necrosis factor (TNF) and in the treatment of asthma, arthritis, bronchitis, chronic obstructive airways disease psoriasis, allergic rhinitis, dermatitis and other inflammatory diseases characterized by phosphodiesterase (PDE) Type IV activity as well as AIDS sepsis, septic shock , and other diseases such as cachexia, involving the production of TNF.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 6, 1995 and granted February 20, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 6, 2015.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 6, 2017.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.